Samsung Biologics expands agreement with Bristol to manufacture antibody cancer substance

 Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company's latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea. 

https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Samsung-Biologics-announces-expanded-strategic-agreement-with-Bristol-Myers-Squibb-to-manufacture-an-44859981/